Navigation Links
Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Date:1/12/2009

ted predictive or prognostic test could be very useful in helping us optimize treatment plans for these patients, potentially sparing them from chemotherapy they do not need."

As previously announced, Genomic Health will present at the 27th Annual JPMorgan Healthcare Conference in San Francisco on Wednesday, January 14 at 10:30 a.m. Pacific Time. To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's Web site at http://investor.genomichealth.com. Please connect to the Web site at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available for three months beginning 24 hours after the live presentation.

About Oncotype DX(R) breast cancer assay

The Oncotype DX breast cancer assay is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer assay has been extensively evaluated in eleven clinical studies involving more than 4,000 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 75,000 tests, and both Medicare and private health plans covering approximately 90 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd.
3. AutoGenomics Invited to Present at the 2009 JPMorgan Healthcare Conference
4. Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
5. Transgenomic Receives Accreditation From College of American Pathologists
6. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
7. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
8. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
9. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
10. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
11. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 24, 2014 2014 Deep ... Industry is a professional and in-depth research report ... Dihydrazide information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Apiscent ... supplier of fine chemical ingredients to the global ... launch of its new website, Apiscent.com. , The ... Apiscent Labs, clean design, easy navigation, rotating images ... Apiscent Labs stand out. , The ...
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), ... scientific testing methodologies relating to cannabis, today announced that ... of credit from an existing stockholder of the Company. ... this commitment from one of our existing stockholders,” stated ... capital will help accelerate our planned expansions into the ...
(Date:11/22/2014)... 22, 2014 Respiratory therapy students ... proper management of life-like respiratory ailments using the ... . Grand Rapids-based, Michigan Instruments Inc. developers of ... of the respiratory simulation units to the pro-gram, ... Valley and Muskegon Community College are collaborating to ...
Breaking Biology Technology:Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3CannLabs Secures $750,000 Line Of Credit 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
(Date:11/3/2014)... Research and Markets has announced the ... Markets and Companies" to their offering. ... which have already started to play an important role in ... the old fashioned bone marrow transplants. Role of cells in ... become a part of medical practice. Stem cells ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
(Date:11/2/2014)... of Physics World , James Dacey explores the ... death" to take their innovations from the lab into ... challenge facing all start-up companies as they move from ... of two main factors: physics-based inventions are usually far ... out to be a lot more complicated than had ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... Ariz. (Sept. 13, 2012) -- Shane Snyder, who earlier ... Water Works Association (AWWA), has been invited to present ... 3,500 at the 2012 International Water Association,s (IWA) World ... professor,s presentation will focus not only on his research ...
... Scientists have found the answer to why female killer whales have ... their adult sons. Led by the Universities of Exeter and York ... the research shows that, for a male over 30, the death ... his death within the following year. The reason for the ...
... of bioengineering at Stanford University, has won a Director,s ... award includes a five-year, $2.5 million grant to be ... to affect a broad area of biomedical or behavioral ... to explore the use of synthetic biology platforms and ...
Cached Biology News:UA engineering professor Shane Snyder to speak in Korea on international water quality 2Long menopause allows killer whales to care for adult sons 2Long menopause allows killer whales to care for adult sons 3
SlowFade Antifade Kit with DAPI...
...
... SAGE (serial analysis of ... genome-wide expression analysis. Expression profiles ... enough to detect low-abundance transcripts ... novel genes. The I-SAGE Kit ...
Mycoplasma tested...
Biology Products: